布地奈德雾化吸入治疗慢性阻塞性肺疾病急性加重期效果观察
摘要：目的：观察布地耐德雾化吸入对慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效。
方法：将60例AECOPD住院患者随机分为治疗组与对照组，治疗组30例患者,在常规治疗的基础上给予布地奈德混悬液1mg+可必特2.5ml联合雾化吸入,对照组30例患者在常规治疗的基础上给予甲强龙40mg静脉滴注，可必特2.5ml雾化吸入。在入院7天时比较两组患者的临床疗效、肺功能情况、治疗前后的血气变化情况，同时观察临床症状及不良反应。
结果：治疗组患者总有效率为83.3%，显著高于对照组的66.7%,P＜0.05；治疗组治疗后的肺功能情况、血气变化均显著优于对照组，P＜0.05。
结论：布地耐德雾化吸入能够改善AECOPD患者肺功能及临床症状,与全身使用糖皮质激素相比疗效更佳，且不良反应明显减少。
关键词：布地耐德 雾化吸入 慢性阻塞性肺疾病急性加重期 糖皮质激素
The effect of inhating Budesonide Suspenion in treatment of acute exacerbations of chronic obstructive pulmonary disease
Wang Cheng Xiao Lu
Abstract:Objective:To observe the effect of inhating budesonide suspenion in treatment of acute exacerbations of chronic obstructive pulmonary disease(AECOPD).
Methods:The 60 patients with AECOPD were randomly divided into two groups, treatment group of 30 cases were given the atomizing inhalation therapy of BudesonideSuspension(1mg) and Combivent (2.5ml) On the basis of conventional therapy; control group of 30 cases were given the treatment of injection of methylprednisolone(40 mg) and Combivent (2.5ml). the two groups are compared in Clinical efficacy、pulmonary function and blood gas changes before and after treatment at seventh day, meanwhile observed the clinical symptoms as well as the side effect．
Result:The total effective rate of the treatment group was 83.3%,which was significantly higher than the control group 66.7%, P<0.05. pulmonary function and blood gas change in treatment group significantly better than the control group, P...
|
== 试读已结束，如需继续阅读敬请充值会员 ==
|
|
本站文章均为原创投稿，仅供下载参考，付费用户可查看完整且有格式内容！
(费用标准：38元/2月，98元/2年，微信支付秒开通！) |
| 升级为会员即可查阅全文 。如需要查阅全文，请 免费注册 或 登录会员 |
|
